Oncology Venture today publishes a supplement to the prospectus published April 5, 2019

NEXT STORY
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
PREV STORY
Basilea shareholders approve all proposals of the Board of Directors at the Annual General Meeting
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates

Positive Phase 2a Proof-of-Concept Data Reported from ANB020 Trials in Atopic Dermatitisand Peanut Allergy ...

author_avatar
NASDAQ Market News

Kamada to Host R&D Day Focused on Graft versus Host Disease (GvHD)

NESS ZIONA, Israel, March 02, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a ...

author_avatar
NASDAQ Market News

Treatment with Novartis’ Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation

Ultibro® Breezhaler® provided significant improvements in cardiac and lung function in COPD patients with ...

author_avatar
NASDAQ Market News